OA09.05 Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study

IF 21 1区医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI:10.1016/j.jtho.2024.09.055

M. Alexander , Y. Cheng , S.-H. Lee , A. Passaro , A.I. Spira , B.C. Cho , S.M. Lim , Y. Ohe , A. Nagrial , J.L. Tan , V. Wainsztein , E. Ramos , M. del Rosario Garcia Campelo , H. Akamatsu , D. Nguyen , A.B. Cortot , A. Zer , D. Erdem , R.E. Sanborn , T.-O. Emde , N.B. Leighl

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

OA09.05 皮下注射与静脉注射阿米万他单抗：PALOMA-3研究的患者满意度和资源利用结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

期刊最新文献

Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450]. Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA). Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer. LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons.